The effects of disease-modifying therapies in SMA-5q type 1 and the importance of early diagnosis of the disease
2024

The Importance of Early Diagnosis and Treatment in Spinal Muscular Atrophy Type 1

Sample size: 10 Editorial Evidence: moderate

Author Information

Author(s): Edmar Zanoteli

Primary Institution: Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil

Hypothesis

Early initiation of disease-modifying therapies improves outcomes in patients with SMA-5q type 1.

Conclusion

The study emphasizes the efficacy of disease-modifying therapies in SMA-5q type 1 and the critical need for early diagnosis and treatment.

Supporting Evidence

  • Early treatment leads to better outcomes in SMA-5q type 1 patients.
  • Gene therapy showed more significant functional gains when started earlier.
  • Patients with more advanced disease had less favorable outcomes.
  • Stability of respiratory and bulbar functions was observed in most patients after treatment.

Takeaway

If kids with a certain disease get treatment early, they can do much better. This study shows that starting treatment quickly is really important.

Methodology

The study assessed the effects of nusinersen and gene therapy on motor, respiratory, and bulbar functions in patients with type 1 SMA-5q.

Potential Biases

Potential bias due to the observational nature of the study and the variability in treatment initiation times.

Limitations

The assessment of respiratory and bulbar functions is challenging in children due to the lack of specific scales and biomarkers.

Participant Demographics

Patients with type 1 spinal muscular atrophy, average age of treatment onset was 30.3 months for nusinersen and 15.2 months for gene therapy.

Digital Object Identifier (DOI)

10.1055/s-0044-1791757

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication